We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
How to make sure your clinical investigation will meet the MHRA's requirements for medical devices.
A letter to community pharmacy contractors to set out the detail of the agreed funding arrangements for community pharmacy.
Links to EU guidance, as it stood immediately before end of transition period.
Guidance for marketing authorisation holders on drafting direct healthcare professional communications (DHPCs)
Resources for pharmacies to achieve Healthy Living Pharmacy (HLP) Level 1 status.
Information to raise awareness with commissioners and providers of the community pharmacy offer for sexual health, reproductive health and HIV services.
Guidance on the steps manufacturers and suppliers can take to ease supply shortages.
How the MHRA makes decisions on whether a borderline product is a medical device or a medicinal product.
How to use PharmaQC to access pharmaceutical suppliers, Quality Control (QC) pharmacists and Commercial Medicines Unit (CMU) buyers.
New Cosmetic Breast Augmentation Risk Awareness Tool for patients to use when considering cosmetic breast implant surgery.
Every year the MHRA receives requests for its staff to speak at conferences and other events across the world.
Guidance for healthcare professionals on risk minimisation options for medicines.
Guidance on how to report suspected adverse incidents and safety concerns with diabetes management equipment to the Yellow Card scheme.
Information on the implementation of changes to the licensing of medicines for human use in the UK following the agreement of the Windsor Framework.
Information relating to parallel imports and the implementation of the Windsor Framework.
The MHRA has published advice for patients and healthcare professionals
The MHRA's initial plans on an Early Access service, which will be developed further throughout 2025.
Guidance to help medicine manufacturers meet safe limits on levels of nitrosamine impurities in medicines.
An overview of the legal requirements for children’s medicines that marketing authorisation holders (MAHs) need to abide by.
Sets out the payment due from members of the voluntary scheme for branded medicines pricing, access and growth in 2025.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).